Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance

Cytokinetics IncTrade
JPMorgan Nasdaq Equity Premium Income ETFTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Cytokinetics Inc trades at $76.22 (market cap $10.63B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $60.05. Which is the better fit depends on your goals.

CYTKJEPQ
Market Cap
$10.63B
Sector
TechnologyIncome / Options Overlay
52-Week High
$87.26$61.46
52-Week Low
$34.31$53.77
Enterprise Value
$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ trades at $60.055, up 0.63% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates consistent monthly income, with recent dividends of $0.70, $0.64, and $0.56. News coverage highlights its role in retirement income strategies alongside tax considerations for distributions. Institutional interest remains strong with Bank of America increasing its stake by 8.9% in Q1 2026.

JEPQ offers attractive yield generation through its Nasdaq-focused options strategy, but investors face tax implications as distributions are taxed as ordinary income. The ETF's performance depends on market volatility for premium collection, creating both opportunity and risk during turbulent periods. Current technical strength supports near-term upside potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About JPMorgan Nasdaq Equity Premium Income ETF

JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.

Read more on JEPQ